Comorbidity Patterns in Patients with Atopic Dermatitis Using Network Analysis in the EpiChron Study.
atopic dermatitis
comorbidities
network analysis
patterns
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
29 Oct 2022
29 Oct 2022
Historique:
received:
18
09
2022
revised:
19
10
2022
accepted:
26
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Background: Atopic dermatitis (AD) is associated with different comorbidities. Methods: Retrospective, observational study based on clinical information from the individuals of the EpiChron Cohort Study (Aragon, Spain) with a diagnosis of AD between 1 January 2010 and 31 December 2018. We calculated the tetrachoric correlations of each pair of comorbidities to analyze the weight of the association between them. We used a cut-off point for statistical significance of p-value < 0.01. Results: The prevalence of AD in the EpiChron Cohort was 3.83%. The most frequently found comorbidities were respiratory, cardio-metabolic, cardiovascular, and mental health disorders. Comorbidities were combined into 17 disease patterns (15 in men and 11 in women), with some sex and age specificities. An infectious respiratory pattern was the most consistently described pattern across all ages and sexes, followed by a cardiometabolic pattern that appeared in patients over 18 years of age. Conclusions: Our study revealed the presence of different clinically meaningful comorbidity patterns in patients with AD. Our results can help to identify which comorbidities deserve special attention in these types of patients and to better understand the physio-pathological mechanisms underlying the disease associations identified. Further studies are encouraged to validate the results obtained in different clinical settings and populations.
Identifiants
pubmed: 36362643
pii: jcm11216413
doi: 10.3390/jcm11216413
pmc: PMC9658108
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III
ID : CM19/00164
Organisme : Instituto de Investigación Sanitaria Aragón
ID : RD21/0016/0019
Organisme : Gobierno de Aragón
ID : B01_20R and DECRETO-LEY 3/2020, de 3 de junio, del Gobierno de Aragón
Organisme : European Union
ID : NextGenerationEU
Organisme : Sanofi-Genzyme
ID : Private financial
Références
Phys Rev E Stat Nonlin Soft Matter Phys. 2009 Nov;80(5 Pt 2):056117
pubmed: 20365053
J Am Heart Assoc. 2017 Sep 9;6(9):
pubmed: 28889101
Int J Epidemiol. 2018 Apr 1;47(2):382-384f
pubmed: 29346556
PLoS One. 2018 Feb 22;13(2):e0193143
pubmed: 29470502
Allergy. 2015 Oct;70(10):1300-8
pubmed: 26148129
Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8577-82
pubmed: 16723398
Psychiatry Res. 2013 Dec 30;210(3):1301-3
pubmed: 24135551
Mech Ageing Dev. 2021 Jan;193:111392
pubmed: 33129797
J Invest Dermatol. 2017 Jan;137(1):18-25
pubmed: 27771048
Am J Clin Dermatol. 2018 Dec;19(6):821-838
pubmed: 30168085
Ann Allergy Asthma Immunol. 2019 Aug;123(2):179-185
pubmed: 31201863
Acta Derm Venereol. 2002;82(2):98-103
pubmed: 12125961
Clin Dermatol. 2014 May-Jun;32(3):409-13
pubmed: 24767188
Ann Allergy Asthma Immunol. 2019 Aug;123(2):144-151
pubmed: 31034875
J Investig Allergol Clin Immunol. 2009;19 Suppl 2:27-33
pubmed: 19530415
J Clin Med. 2020 May 28;9(6):
pubmed: 32481591
Eur J Dermatol. 2022 Feb 1;32(1):34-48
pubmed: 34911672
J Allergy Clin Immunol. 2019 May;143(5):1821-1829
pubmed: 30576754
Allergy Asthma Clin Immunol. 2021 Sep 22;17(1):94
pubmed: 34551806
Eur Respir J. 2015 Sep;46(3):640-50
pubmed: 26160874
Allergy. 2015 Jul;70(7):836-45
pubmed: 25832131
J Allergy Clin Immunol. 2014 Apr;133(4):1041-7
pubmed: 24094542